Ann Surg Oncol (2018) 25:1803–1806 https://doi.org/10.1245/s10434-018-6516-4 EDITORIAL – MELANOMAS Revolutionary Advances in Immunotherapy for Melanoma Are Coming into the Surgical Arena: Are We Ready? Charles M. Balch, MD, FACS, FASCO University of Texas MD Anderson Cancer Center, Houston, TX In the past decade, powerful new immunotherapy agents vaccines have failed in the past decades. Thus, in a ‘‘tol- have demonstrated remarkable improvements in survival of erant state,’’ most cancer patients cannot respond to patients with many histological types of stage IV cancer, as treatment approaches that involve increased antigen pre- ﬁrst demonstrated in metastatic melanoma and reported in sentation (e.g., vaccines) or immune stimulants (e.g., 2010. With a new understanding of the immune system interferons or interleukins). With the availability of and a growing portfolio of powerful immunotherapy checkpoint inhibitors to ‘‘break tolerance,’’ the immune agents, survival rates in stage IV melanoma patients have system can now recognize and destroy metastases as it dramatically increased from a historical median survival of would any ‘‘foreign invader,’’ such as viruses or trans- 2–9 months, to a remarkable median survival exceeding planted tissues. With multiple checkpoint inhibitors 24 months, with approximately 20% of patients remaining approved for cancer, an entirely new landscape
Annals of Surgical Oncology – Springer Journals
Published: May 11, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud